GlassScriptPhysician profile
Kenneth John Mcalpine
NPI 1023351194
$12,723.28
in general payments reported to CMS, 2019-2025
13 companies · $7,747 in 2025
The $7,747 reported for 2025 was more than what 86% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,101 · 2020: $20.69 · 2021: $289 · 2022: $1,522 · 2023: $400 · 2024: $1,644 · 2025: $7,747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $7,410 · Food and Beverage: $1,232 · Travel and Lodging: $1,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $7,409.92 |
| Food and Beverage | $1,232.24 |
| Travel and Lodging | $1,148.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nextstep Arthropedix, LLC | $7,549.24 | 2022-2025 | Insitu Hip System |
| Stryker Corporation | $3,428.05 | 2019-2025 | Mako, Triathlon, Restoration |
| Pacira Pharmaceuticals Incorporated | $1,030.42 | 2022 | |
| Zimmer Biomet Holdings, INC. | $217.22 | 2019-2025 | Persona |
| Smith+Nephew, INC. | $141.72 | 2019 | |
| Conformis, INC. | $104.09 | 2021 | |
| Depuy Synthes Sales INC. | $93.13 | 2022 | |
| Medical Device Business Services, INC. | $77.10 | 2021-2023 | Actis |
| Daiichi Sankyo INC. | $20.69 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $18.79 | 2025 | |
| Avanos Medical | $15.67 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.62 | 2023 | Seglentis |
| Glaxosmithkline, LLC. | $13.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Mcalpine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.